91209-87-9

Upstream product

• 68619-18-1 9,10-Dimethoxy-3,4,6,7-tetrahydro-2H-pyrimido(6,1-a)isoquinolin-2,4-dione 
• 75535-95-4 1-<2-(3,4-Dimethoxyphenyl)ethyl>pyrimidin-2,4,6(1H,3H,5H)-trion 
• 25017-47-4 N-<2-(3,4-dimethoxyphenylethyl)>urea 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 75535-96-5 2-Chloro-9,10-dimethoxy-6,7-dihydro-4H-pyrimido(6,1-a)isoquinolin-4-one 
• 91209-74-4 1-(carbamoylmethylene)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 

Relevant academic research and scientific papers

Trequinsin, a potent new antihypertensive vasodilator in the series of 2-(arylimino)-3-alkyl-9,10-dimethoxy-3,4,6,7-tetrahydro-2H-pyrimido[6,1 -a]isoquinolin-4-ones

Series of 3-substituted-9,10-dimethoxy-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquino line-2,4-diones and 2-substituted-9,10-dimethoxy-6,7-dihydro-4H-pyrimido[6,1-a]isoquinolin-4- ones were synthesized and tested for blood pressure lowering properties in anesthetized normotensive cats and conscious spontaneously hypertensive rats. Several compounds in the 2-(arylimino)-9,10-dimethoxy-6,7-dihydro-4H-pyrimido[6,1-a]isoquinolin-4-o ne series display a high order of activity. The most active compounds are the alkyl derivatives of the 2-mesitylamino/2-mesitylimino tautomeric forms. The 2-(mesitylimino)-3-methyl analogue trequinsin is a potent antihypertensive agent and displays a hemodynamic profile characteristic of an anterior dilator. It is also a potent inhibitor of both cAMP phosphodiesterase and platelet aggregation.